, Tracking Stock Market Picks
Enter Symbol:

down 7.74 %

MEDIVATION INC (MDVN) rated Buy with price target $132 by Canaccord Genuity

Posted on: Thursday,  Sep 18, 2014  9:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Buy MEDIVATION INC (NASDAQ: MDVN) on 09/18/2014, when the stock price was $99.80. Since
then, MEDIVATION INC has lost 7.75% as of 01/27/2016's recent price of $92.07.
If you would have followed this Canaccord Genuity's recommendation on MDVN, you would have lost 7.74% of your investment in 496 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/27/2016 9:25 AM Hold
34.96 45.00
as of 10/17/2014
1 Week up  1.36 %
1 Month down  -5.54 %
3 Months   
1 YTD down  -5.54 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/8/2015 9:25 AM Buy
129.60 180.00
9/18/2014 9:25 AM Buy
99.80 132.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy